Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
1. A ready-to-use injectable pharmaceutical composition comprising:
(i) about 0.5 mg/mL of neostigmine or a pharmaceutically acceptable salt, solvate or hydrate thereof;
(ii) about 0.1 mg/mL of glycopyrrolate or a pharmaceutically acceptable salt, solvate or hydrate thereof;
and (iii) a pharmaceutically acceptable liquid vehicle,
wherein a level of Glycopyrrolate Impurity C in the composition is less than 1% when stored at 40° C. and 75% relative humidity for at least 3 months wherein the composition has a pH ranging from about 3.0 to about 4.0.
2. The pharmaceutical composition according to claim 1 , comprising neostigmine methylsulfate and glycopyrronium bromide.
3. The pharmaceutical composition according to claim 1 , wherein the composition is provided in a sealed container selected from the group consisting of a vial and a pre-filled syringe.
4. The pharmaceutical composition according to claim 1 , wherein the composition is provided in a clear glass vial, an amber glass vial, a plastic vial or a pre-filled syringe.
5. The pharmaceutical composition according to claim 1 , wherein the composition is in the form of a solution.
6. The pharmaceutical composition according to claim 1 , wherein the composition is suitable for subcutaneous, intravenous or intramuscular administration.
7. The pharmaceutical composition according to claim 1 , wherein the composition has a pH ranging from about 3.0 to about 3.5.
8. The pharmaceutical composition according to claim 1 , further comprising a tonicity modifier.
9. The pharmaceutical composition according to claim 8 , wherein the tonicity modifier is selected from the group consisting of glycerine, lactose, mannitol, dextrose, sodium chloride, sodium sulphate, sorbitol, and trehalose.
10. The pharmaceutical composition according to claim 8 , wherein the tonicity modifier is present in an amount from about 1 mg/mL to about 20 mg/mL of the composition.
11. The pharmaceutical composition according to claim 8 , wherein the tonicity modifier is present in an amount from about 5-10 mg/mL.
12. The pharmaceutical composition according to claim 1 , which is stable for at least 3 months at 25° C. and 60% relative humidity.
13. The pharmaceutical composition of claim 1 , wherein the level of Glycopyrrolate Impurity C is less than 1% (w/w) as measured by HPLC.
14. The pharmaceutical composition of claim 1 , wherein the composition is sterilized.
15. The pharmaceutical composition of claim 1 , wherein the composition is sterilized using a technique selected from the group consisting of filtration through a bacterial-retaining filter, terminal sterilization, incorporation of sterilizing agents, irradiation, and heating.
16. The pharmaceutical composition of claim 1 , wherein the composition is sterilized using a technique selected from the group consisting of aseptic filling, irradiation and heat sterilization.
17. A method for treating a neuromuscular disease, comprising administering the pharmaceutical composition according to claim 1 to a patient in need thereof.